EISAI CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,052 JPY | +0.67% |
|
-1.27% | -14.18% |
| Apr. 01 | Cogstate Amends License Agreement with Eisai for Alzheimer’s Treatment | MT |
| Apr. 01 | BioArctic, Eisai Seek US FDA Approval for Maintenance Dose of Alzheimer’s Disease Drug | MT |
| Sales 2024 * | 735B 4.77B | Sales 2025 * | 779B 5.06B | Capitalization | 1,733B 11.25B |
|---|---|---|---|---|---|
| Net income 2024 * | 41.12B 267M | Net income 2025 * | 50.09B 325M | EV / Sales 2024 * | 2.12 x |
| Net cash position 2024 * | 172B 1.12B | Net cash position 2025 * | 184B 1.19B | EV / Sales 2025 * | 1.99 x |
| P/E ratio 2024 * |
42.3
x | P/E ratio 2025 * |
34.8
x | Employees | 11,076 |
| Yield 2024 * |
2.68% | Yield 2025 * |
2.75% | Free-Float | 93.84% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eisai Co., Ltd.
More recommendations
More press releases
| 1 day | -0.48% | ||
| 1 week | -1.75% | ||
| Current month | -3.28% | ||
| 1 month | -4.68% | ||
| 3 months | -20.20% | ||
| 6 months | -27.52% | ||
| Current year | -14.75% |
1 week
5 923.00
6 143.00
1 month
5 885.006 468.00
Current year
5 885.007 818.00
1 year
5 885.0011 250.00
3 years
5 011.0012 765.00
5 years
5 011.0012 765.00
10 years
3 860.0012 765.00
| Managers | Title | Age | Since |
|---|---|---|---|
Haruo Naito
CEO | Chief Executive Officer | 76 | 75-09-30 |
Mitsuru Shomon
DFI | Director of Finance/CFO | - | - |
Makoto Hoketsu
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Haruo Naito
CEO | Chief Executive Officer | 76 | 75-09-30 |
Fumihiko Ike
BRD | Director/Board Member | 71 | 21-05-31 |
Toru Moriyama
BRD | Director/Board Member | 69 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 5.78% | 15 M€ | +5.02% | ||
| 1.23% | 251 M€ | +15.45% | ||
| 1.13% | 31,732 M€ | +18.19% | - | |
| 1.12% | 1,198 M€ | +17.03% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-16 | 6,052 | +0.67% | 797 900 |
| 24-04-15 | 6,012 | -0.48% | 648,000 |
| 24-04-12 | 6,041 | +1.21% | 776,900 |
| 24-04-11 | 5,969 | -0.81% | 754,600 |
| 24-04-10 | 6,018 | -1.83% | 622,900 |
Delayed Quote Japan Exchange, April 15, 2024 at 02:00 am EDT
More quotes
Eisai Company specializes in the manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceutical products (87.7%): prescribed drugs, health products, etc.;
- other (12.3%): food additives, chemical products, etc.
Net sales are distributed geographically as follows: Japan (46.2%), Europe (19.5%), Americas (15.5%), China (10.3%) and other (8.4%).
Sector
Pharmaceuticals
Calendar
2024-05-14
- Q4 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
6,041
JPY
Average target price
8,336
JPY
Spread / Average Target
+37.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.75% | 11.32B | |
| +28.94% | 677B | |
| +26.87% | 560B | |
| -5.88% | 355B | |
| +4.72% | 287B | |
| +3.89% | 214B | |
| +1.65% | 207B | |
| -7.89% | 199B | |
| -10.18% | 146B | |
| -7.20% | 143B |
- Stock Market
- Equities
- 4523 Stock
